Loncipoetin alfa (NuPIAO) vs RD01 (PEG-EPO)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
Loncipoetin alfa (NuPIAO)
Marketed by Shenyang Sunshine Pharmaceutical
NCT05211167 · Phase 3 · status unknown
This is a randomized, active-controlled Phase 3 trial with an adequately sized enrollment comparing the study drug against a standard recombinant erythropoietin, using change in hemoglobin, the measure that defines the anemia being treated, as its primary endpoint. However, the trial was not blinded, and results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Reported efficacy
hemoglobin concentration (25th-32nd week): Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given. (met)
Result source: NCT05211167
RD01 (PEG-EPO)
Developed by Shenzhen Sciprogen Bio-pharmaceutical
NCT04231292 · Phase 2 · status unknown
This is a randomized, controlled trial (active and placebo comparator arms) using hemoglobin concentration, the disease-defining measure for anemia, as its primary endpoint, but only participants were masked (not investigators or assessors), and no results have yet been posted.
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Loncipoetin alfa (NuPIAO) | RD01 (PEG-EPO) |
|---|---|---|
| Kidney composite outcome | —Not reported | —Not reported |
| UACR, % change | —Not reported | —Not reported |
| eGFR slope | —Not reported | —Not reported |
| Haemoglobin, change | —Not reported | —Not reported |
Kidney composite outcome
- Loncipoetin alfa (NuPIAO)
- —Not reported
- RD01 (PEG-EPO)
- —Not reported
UACR, % change
- Loncipoetin alfa (NuPIAO)
- —Not reported
- RD01 (PEG-EPO)
- —Not reported
eGFR slope
- Loncipoetin alfa (NuPIAO)
- —Not reported
- RD01 (PEG-EPO)
- —Not reported
Haemoglobin, change
- Loncipoetin alfa (NuPIAO)
- —Not reported
- RD01 (PEG-EPO)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
RD01 (PEG-EPO): no structured comparison results are available for Chronic Kidney Disease.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loncipoetin alfa (NuPIAO)'s landscape · RD01 (PEG-EPO)'s landscape